THYROID DISEASES -- Diagnosis and treatment of hyperthyroidism (Endocrinologist) -- Radiopharmaceuticals for therapy of thyroid diseases ( chemistry, mechanism of uptake, biodistribution, doses) (Radiochemist) -- Radioiodine therapy of hyperthyroidism (indications , procedures and results) ( Nucl Medicine Physician) -- Dosimetry (Physicist) -- Clinical management of thyroid cancer (Oncologist) -- Radioidine therapy of thyroid cancer (ablation, loco-regional and distant metastases, indications procedures and results) (Nucl Medicine Physician) -- Dosimetry (Physicist) -- Novel approaches of radiometabolic treatment of thyroid cancer (Nucl Medicine Physician) -- Published guidelines on radioisotopic treatments of thyroid diseases (Nucl Medicine Physician and Oncologist) -- HEPATIC CANCER -- Clinical options for treatment of hepatocellular carcinoma (HCC) (Oncologist, Surge on) -- Radiopharmaceuticals for radioembolization (characteristics, mechanism of uptake, biodistribution, doses) (Radiochemist) -- HCC radioembolization with 90Y microspheres (indications and procedures) (Nucl Medicine Physician) -- Dosimetry (Physicist) -- The clinical problem of hepatic metastases (Oncologist, Surgeon) -- Radioembolization of hepatic metastases with 90Y microspheres (indications and procedures) (Nucl Medicine Physician) -- Dosimetry (Physicist) -- Published guidelines on radioisotope treatment of hepatocellular cancer (Nucl Medicine Physician and Oncologist) -- NEUROENDOCRINE TUMORS -- Radiopharmaceuticals for treatment of neuroendocrine tumors (mechanisn of action, biodistribution, doses) (Radiochemis inPaediatric tumors of neuroendocrine origin (Oncologist) -- Treatment with 131I - MIBG (indications procedures and results) (Nucl Medicine Physician) -- Dosimetry (Physicist) -- GEP neuroendocrine tumors (Oncologist) -- PPRT with 90Y labeled peptides (indications ,procedures and results) (Nucl Medicine Physician) -- Dosimetry (Physicist) -- Published guidelines on radioisotope treatment of Neuroendocrine tumors(Nucl Medicine Physician and Oncologist) -- LYMPHOMAS -- Selection of lymphoma patients candidates for Radioimmunotherapy (Haematologist) -- Radiopharmaceuticals for treatment of neuroendocrine tumors (mechanisn of action, biodistribution, doses) (Radiochemist) -- Treatment with anti-CD20 Antibodies ( 90Y- ibritumomab /131 I- Tositumomab) (indications and procedures and results) (Nucl Medicine Physician) -- Radioimmunotherapy at high doses of lymphomas (Nucl Medicine Physician) -- Published guidelines on radioisotope treatment of Lymphomas (Nucl Medicine Physician and Oncologist) -- PROSTATE CANCER -- Overview on bone metastases from prostate cancer (Urologist, Oncologist) -- Radiopharmaceuticals for treatment of bone metastases (mechanisn of action, biodistribution, doses) (Radiochemist) -- Targeted therapy with 223Ra dichloride of bone metastases(Nucl Medicine Physician) -- Novel approaches of treatment with 223Ra based targeted therapy (Nucl Medicine Physician) -- Dosimetry (Physicist) -- Published guidelines on radioisotope treatment of Bone Metastases (Nucl Medicine Physician and Oncologist).

This book offers a practical and modern update on radioisotope therapy. Clinically oriented, it provides a thorough guide to patient management, with the latest indications and procedures for the current radioisotopic treatments. It addresses the clinical problems associated with each respective pathology, discussing the management of patients (diagnosis and non-radioisotope therapy), the radiopharmaceuticals available today, and the current radioisotopic procedures. Wherever possible, information on dosimetry is included at the end of each topic, together with a list of and comments on the most recent guidelines with their recommendations for radiometabolic therapy. The book is divided into six main sections: thyroid diseases, hepatic tumors (HCC and hepatic metastases), bone metastases from prostate cancer, lymphomas, and neuroendocrine tumors. The last section is dedicated to new perspectives of radioisotope treatment. Based on contributions from of a multidisciplinary team of specialists: oncologists, surgeons, endocrinologists, hematologists, urologists, radiopharmacists and nuclear medicine physicians, it provides a comprehensive analysis of the position of radioisotope treatments among the various therapeutic options. Readers interested in targeted therapy, radiometabolic therapy, radioimmunotherapy and radiometabolic imaging will find this book both informative and insightful.